ONY is currently a leader in the Neonatology market and is committed to delivering critically important products for the treatment of premature infants.

ONY’s first commercial product, Infasurf (calfactant), is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (“rescue”) of premature infants who develop RDS.

Infasurf is approved and available for use in the United States and approved in 13 countries around the world.